236 million. The number of lives that were touched by Novartis medicines in 2022!
Job Purpose
The Director of Portfolio Analytics will provide real-time portfolio insights and analysis to senior leadership, key stakeholders, and cross-divisional counterparts. This will support strategic decision-making, portfolio prioritization, and generate a common understanding of pipeline status. The Director will also drive the characterization of the portfolio's current state, performance against metrics, and future evolution for internal and external purposes
Major Accountabilities
- Leads portfolio assessment and regular, high quality pipeline insights to provide a real-time holistic picture of the Novartis pipeline including impact of recent internal and external events and decisions on short, mid- and long-term growth to key stakeholders
- Provides analyses and insights in close collaboration with Divisional counterparts, Corporate & TA Strategy, and Portfolio Strategy & Analytics colleagues and other key stakeholders to drive real-time portfolio review and prioritization deep dives for portfolio governance and inform the ECN (C-Suite) Strategy Meeting as a part of the annual strategic planning cycle, driving the sustainable delivery of transformative medicines in the short-, mid- and long-term
- Creates and maintains regular reporting on the pipeline in dimensions of value, strategic fit and execution to internal and external stakeholders
- Evaluates and reports on key changes in sales forecasts and/or value for in-line brands and pipeline portfolio to Governance and other senior stakeholders, and establishes a standard approach for regular reporting of catalyst/challenge events and their impact on forecasts/value
- Drives insights to inform Governance decision-making on portfolio trade-offs involving internal and external (BD&L) projects to achieve growth goals subject to investment constraints by preparing an independent individual project assessment and position within the portfolio in collaboration with Strategy & Growth colleagues and other key stakeholders
- Develops and delivers in-depth analyses and strategic insights into the drug pipeline/portfolio addressing senior management questions (including ECN and Board of Directors)
- Provides pipeline information including changes for external reporting (e.g., 20F, Annual Report, and other IR-related events) by establishing and maintaining systems and processes in liaison with key stakeholders across the organization. Establishes and drives innovative portfolio tools to capture standardized inputs for reporting and project/portfolio assessments, including financial valuations, scenario planning and pipeline modelling
- Contributes towards the continued build out of the newly integrated Portfolio Strategy & Analytics function and acts as an influential ambassador and portfolio expert to the rest of Novartis
This is a site based role in Cambridge, MA.
The pay range for this position at commencement of employment is expected to be between $192,000 and $288,000 per year; however, while salary ranges are effective from 1/1/24 through 12/31/24, fluctuations in the job market may necessitate adjustments to pay ranges during this period. Further, final pay determinations will depend on various factors, including, but not limited to geographical location, experience level, knowledge, skills and abilities. The total compensation package for this position may also include other elements, including a sign-on bonus, restricted stock units, and discretionary awards in addition to a full range of medical, financial, and/or other benefits (including 401(k) eligibility and various paid time off benefits, such as vacation, sick time, and parental leave), dependent on the position offered. Details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors